Holen Sie sich die Stockscreener-App
60.03
5.60%
-3.56
Handel nachbörslich:
60.02
-0.010
-0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$63.59
Offen:
$63.49
24-Stunden-Volumen:
2.14M
Relative Volume:
0.95
Marktkapitalisierung:
$7.18B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-11.41
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
-0.25%
1M Leistung:
+5.37%
6M Leistung:
+60.72%
1J Leistung:
+15.84%
1-Tages-Spanne:
$59.11
$63.96
1-Wochen-Bereich:
$59.11
$64.13
52-Wochen-Spanne:
$29.31
$64.13
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
60.03 | 7.61B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
CYTOKINETICS CLASS ACTION: Bragar Eagel & Squire, P.C. - GlobeNewswire
Key facts: Cytokinetics shares plunge; class action lawsuit filed - TradingView
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Morningstar
Nisa Investment Advisors LLC Decreases Holdings in Cytokinetics, Incorporated $CYTK - Defense World
The Gross Law Firm Notifies Cytokinetics, Incorporated Investors of a Class Action Lawsuit and Upcoming DeadlineCYTK - PR Newswire
35,600 Shares in Cytokinetics, Incorporated $CYTK Purchased by Zweig DiMenna Associates LLC - MarketBeat
November 17, 2025 Deadline: Join Class Action Lawsuit Against Cytokinetics, Incorporated (CYTK)Contact Levi & Korsinsky - ACCESS Newswire
Can Cytokinetics Incorporated (KK3A) stock test all time highsJuly 2025 Catalysts & Entry and Exit Point Strategies - newser.com
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Key metrics from Cytokinetics Incorporated’s quarterly dataEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
How Cytokinetics Incorporated stock benefits from strong dollarJuly 2025 Gainers & Weekly Breakout Opportunity Watchlist - newser.com
Should I buy Cytokinetics Incorporated (KK3A) stock before earnings season2025 Price Momentum & High Return Stock Watch Alerts - newser.com
Does Cytokinetics Incorporated qualify in momentum factor screening2025 Market Sentiment & Fast Moving Stock Trade Plans - newser.com
Key facts: Cytokinetics' stock drops 12.98% after FDA delay; lawsuit filed - TradingView
CYTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cytokinetics, Incorporated Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
What MACD and RSI say about Cytokinetics Incorporated2025 Institutional Moves & Weekly High Potential Alerts - newser.com
Cytokinetics Incorporated recovery potential after sell off2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Pinnacle Associates Ltd. Reduces Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Why analysts remain bullish on Cytokinetics Incorporated stockMarket Movers & AI Enhanced Execution Alerts - newser.com
Is Cytokinetics Incorporated stock positioned for long term growthPortfolio Value Report & Expert Approved Momentum Ideas - newser.com
Key facts: Cytokinetics shares fall 12.98% amid FDA delay; lawsuit filed - TradingView
Cytokinetics (NASDAQ:CYTK) Reaches New 1-Year HighHere's Why - MarketBeat
Robert Blum Sells 5,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, - GlobeNewswire
Cytokinetics, Inc. Hits New 52-Week High at USD 64.13 - Markets Mojo
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - MarketScreener
Cytokinetics Announces Upcoming Late Breaking Science Presentations on Aficamten at Major Cardiovascular Conferences - Quiver Quantitative
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical ... - nrtoday.com
Cytokinetics (NASDAQ: CYTK) to present at HCMS and AHA 2025; 3 MAPLE-HCM Late-Breaking - Stock Titan
How sentiment analysis helps forecast Cytokinetics IncorporatedMarket Performance Recap & Weekly Stock Performance Updates - newser.com
Analyzing recovery setups for Cytokinetics Incorporated investorsJuly 2025 Market Mood & Daily Oversold Stock Bounce Ideas - newser.com
What dividend safety score for Cytokinetics Incorporated stock2025 Volume Leaders & Smart Allocation Stock Tips - newser.com
Applying Elliott Wave Theory to Cytokinetics IncorporatedJuly 2025 Catalysts & Long-Term Capital Growth Strategies - newser.com
Is Cytokinetics Incorporated stock a smart buy before Fed meetingJuly 2025 Short Interest & Fast Moving Stock Watchlists - newser.com
How to track smart money flows in Cytokinetics IncorporatedQuarterly Portfolio Report & AI Enhanced Execution Alerts - newser.com
Blum, Cytokinetics CEO, sells $314k in stock By Investing.com - Investing.com Australia
Cytokinetics stock hits 52-week high at 63.87 USD By Investing.com - Investing.com Canada
Investors SueWallSt as Cytokinetics, Incorporated Faces Securities Fraud Allegations - Nasdaq
Blum, Cytokinetics CEO, sells $314k in stock - Investing.com
Cytokinetics (CYTK): Exploring Valuation After Recent Share Price Momentum and Growth Narrative - Yahoo Finance
Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law ... - Caledonian Record
Cytokinetics, Incorporated Securities Fraud Class Action - GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) - GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Cytokinetics stock hits 52-week high at 63.87 USD - Investing.com
Cytokinetics (CYTK) to Release Earnings on Wednesday - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Bought by State of New Jersey Common Pension Fund D - MarketBeat
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - GlobeNewswire Inc.
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):